About

Provided by Kirkland & Ellis

Our capital markets team in Asia offers a full range of equity and debt capital markets products to our clients in the region, our cutting-edge advantages include over capital markets attorneys and legal professionals in the Hong Kong, Beijing and Shanghai offices working together as one team to provide a full spectrum of services to clients in the region, including HK IPOs, US IPOs, SPAC IPOs and other convertible bond, high yield and investment grade debt and follow-on offerings and PIPE transactions.

Recent work highlights include:

  • Kirkland & Ellis advised Contemporary Amperex Technology Co., Limited (CATL, HKEx: 3750) on its global offering and listing on the Main Board of the Hong Kong Stock Exchange.
  • Kirkland & Ellis advised NIO Inc. (“NIO”) (NYSE: NIO; HKEx: 9866; SGX: NIO) in connection with its HK$4,030.13 million offering of 136,800,000 class A ordinary shares.
  • Kirkland & Ellis represented the joint sponsors, including UBS Securities Hong Kong Limited, China International Capital Corporation Hong Kong, Ping An of China Capital (Hong Kong) Company Limited and GF Capital (Hong Kong) Limited, on the initial public offering of OmniVision Integrated Circuits Group, Inc. (OmniVision, SH: 603501, HKEX: 0501) on the Main Board of the Hong Kong Stock Exchange.

Chambers Review

Provided by Chambers

Capital Markets: Equity (International Firms) - China

2
Band 2

What the Team is Known For

Kirkland & Ellis has a strong track record of acting for international and local businesses and investment banks on US and Hong Kong IPOs. It additionally handles a range of secondary offerings in Hong Kong and New York and maintains strong relationships with regulators. As a Hong Kong and New York-qualified team with Chinese language capabilities, Kirkland & Ellis is well placed to advise on listings on a variety of stock exchanges. It often advises on significant deals in China's TMT and life sciences sectors.

Work Highlights

  • Kirkland & Ellis advised NIO on its HKD4.03 billion offering of 136.8 million Class A ordinary shares at an offering price of HKD 29.46 per share.

  • Kirkland & Ellis advised Contemporary Amperex Technology (CATL) on its global offering and listing on the Main Board of the Hong Kong Stock Exchange.

Strengths

Provided by Chambers

Notable Practitioners

Provided by Chambers

Mengyu Lu
3
Mengyu Lu
3
Band 3

Lu Mengyu has notable experience acting for life sciences and biotech clients, with a strong track record of advising on 18A IPOs.

Mengyu successfully solved a problem that was originally considered unsolvable and proposed a creative and feasible solution.

Dr. Lu attaches equal importance to strategic thinking and practical implementation, ensuring the project is progressing steadily and delivered on schedule with synergy between all parties.

With her leadership and ability to integrate resources and coordinate projects she efficiently mobilises teams and cross-regional resources at all critical stages to ensure they can be delivered.

Ranked Lawyers at
Kirkland & Ellis

Provided by Chambers
Filter by
Band

China

Capital Markets: Equity (International Firms)

Mengyu Lu
3
Mengyu Lu
3
Band 3

Members

Provided by Kirkland & Ellis